-
動態
3月5日下午，北京積水潭醫院鄭州醫院（鄭州市中心醫院）成功舉辦LVA手(shou)術(shu)治(zhi)療(liao)阿(e)爾(er)茨(ci)海(hai)默(mo)病(bing)中(zhong)德(de)研(yan)討(tao)會(hui)。會(hui)議(yi)由(you)醫(yi)院(yuan)黨(dang)委(wei)書(shu)記(ji)馬(ma)西(xi)文(wen)教(jiao)授(shou)以(yi)全(quan)英(ying)語(yu)致(zhi)歡(huan)迎(ying)辭(ci)，由(you)鄭(zheng)州(zhou)大(da)學(xue)創(chuang)傷(shang)與(yu)代(dai)謝(xie)研(yan)究(jiu)院(yuan)執(zhi)行(xing)院(yuan)長(chang)葉(ye)建(jian)平(ping)教(jiao)授(shou)主(zhu)持(chi)。神(shen)經(jing)內(nei)科(ke)、老年醫學科、顯微外科、檢驗科、病理科、影像科、麻醉科等多個相關學科團隊共約80人參會，現場學術氛圍濃厚。研討會特別邀請到德國哥廷根大學醫療中心精神病學與心理治療科主任Wiltfang教授，他圍繞阿爾茨海默病的發病機製、診斷方法、疾病分期及生物標誌物在早期篩查和預防性治療中的應用進行了深入講解。Wiltfang教授指出，阿爾茨海默病的病理變化早在症狀出現前15 - 20年就已開始，主要表現為β澱粉樣蛋白（Aβ）沉積和Tau蛋白異常。當前PET掃描和腦脊液（CSF）檢測雖然準確，但因費用高或具有侵入性，難以在大規模篩查中推廣。因此，血漿生物標誌物檢測因其便捷、微創、低成本的優勢，成為全球研究的熱點。他詳細介紹了其團隊自主研發的Aβ-IP-IA & Tau-IP-IA血漿檢測技術，這一方法結合了免疫沉澱（IP）和高靈敏度免疫檢測（IA），可精準檢測Aβ1-42/1-40比值和p-Tau217水平。在臨床研究中，該方法對早期阿爾茨海默病高風險個體的識別準確率高達91%，並可在症狀出現15年前檢測到病變。此外，研究團隊提出了AT-RATIO這一全新血漿診斷指標，相較於單一生物標誌物檢測，該指標可進一步提高阿爾茨海默病的早期篩查精準度。Wiltfang教授強調，早期診斷對於阿爾茨海默病的幹預至關重要。研究發現，在MCI階段（輕度認知障礙）前即啟動抗Aβzhiliao，bujinkexianzhutigaoliaoxiao，hainengjianshaofuzuoyong。yinci，xuejiangshengwubiaozhiwujiancebujinkeyiyongyudaguimoshaizha，hainengweigetihuazhiliaotigongzhongyaozhidao，youhuakangAβ藥yao物wu的de使shi用yong策ce略lve，為wei阿e爾er茨ci海hai默mo病bing的de早zao期qi幹gan預yu和he預yu防fang性xing治zhi療liao帶dai來lai新xin的de可ke能neng。隨sui後hou，葉ye建jian平ping教jiao授shou全quan英ying文wen分fen享xiang了le醫yi院yuan認ren知zhi中zhong心xin的de診zhen療liao現xian狀zhuang，並bing圍wei繞rao脂zhi代dai謝xie紊wen亂luan與yu阿e爾er茨ci海hai默mo病bing的de關guan係xi及jiLVA手術治療阿爾茨海默病的機製與療效展開講解。Wiltfang教授對這一研究方向表現出極大興趣，雙方研究重點高度契合，討論熱烈，會議超時20分fen鍾zhong仍reng意yi猶you未wei盡jin，並bing約yue定ding未wei來lai繼ji續xu深shen化hua交jiao流liu，共gong同tong推tui動dong阿e爾er茨ci海hai默mo病bing的de早zao期qi診zhen斷duan與yu創chuang新xin治zhi療liao。此ci次ci研yan討tao會hui不bu僅jin促cu進jin了le中zhong德de雙shuang方fang的de深shen入ru合he作zuo，也ye為wei阿e爾er茨ci海hai默mo病bing的de早zao期qi篩shai查zha和he創chuang新xin治zhi療liao提ti供gong了le新xin思si路lu。期qi待dai未wei來lai更geng多duo國guo際ji交jiao流liu，共gong同tong推tui進jin這zhe一yi全quan球qiu難nan題ti的de解jie決jue！
On the afternoon of March 5, the Sino-German Webinar on LVA Treating Alzheimer’s Disease (AD) was successfully held at Beijing Jishuitan Hospital, Zhengzhou Hospital (Zhengzhou Central Hospital).The event was officially opened with a welcome speech in English by Prof. MA Xiwen, Party Secretary of the hospital, and was chaired by Prof. YE Jianping, Executive Director of the Institute of Trauma and Metabolism at Zhengzhou University. The webinar attracted about 80 participants from multiple departments, including neurology, geriatric medicine, microsurgery, laboratory medicine, pathology, radiology, and anesthesiology, fostering a strong academic atmosphere. The webinar featured Prof. Wiltfang, Director of the Department of Psychiatry and Psychotherapy at the University Medical Center Göttingen, Germany. He delivered an in-depth lecture on the validated core neuropathology of Alzheimer’s disease, the current clinical model of AD and the CSF and blood based early and differential diagnosis of AD, with a focus on the clinical relevance of blood based preclinical diagnosis of AD in view of first preventive treatment options. Prof. Wiltfang highlighted that pathological changes in Alzheimer’s disease begin 15-20 years before clinical symptoms appear, primarily characterized by deposits of the β-amyloid peptide (Aβ) and the flame-shaped neurofibrillary tangles of the microtubule binding protein tau. Although cerebrospinal based neurochemical dementia diagnostics (CSF-NDD) and Amyloid-PET offer high diagnostic accuracy, their high cost and invasiveness limit the feasibility for large-scale screening. As a result, Blood based neurochemical dementia diagnostics (Blood-NDD) - with their advantages of convenience, minimal invasiveness, and low cost - have become a global research hotspot. Prof. Wiltfang introduced the IP-IA developed by his team, a novel assay platform combining initial robotic immunoprecipitation (IP) and second step commercially available high throughput capable immunoassay technologies (IA) to precisely measure Aβ1-42/Aβ1-40 ratio and p-Tau217 levels. Clinical studies have shown that this method can identify high-risk individuals with 91% accuracy and detect pathological changes up to 15 years before symptom onset. Additionally, his team proposed a new AT-RATIO offering a single cut-off value: Aβ1-40/1-42 * phospho-Tau217, which improves early screening accuracy compared to single-biomarker detection. Prof. Wiltfang emphasized that early diagnosis is crucial for effective intervention in Alzheimer’s disease. Research shows that initiating reducing-Aβ therapy before the Mild Cognitive Impairment (MCI) stage not only significantly enhances treatment efficacy but also reduces side effects. Blood plasma assays not only facilitates large-scale screening but also provides critical guidance for personalized treatment, helping optimize reducing-Aβ pharmacological strategies and offering new possibilities for early intervention and preventive therapy.Following this, Prof. YE Jianping delivered an English presentation on the hospital’s cognitive center and elaborated on the relationship between lipid metabolism disorders and Alzheimer’s disease, as well as the mechanism and efficacy of LVA surgery for AD treatment. Prof. Wiltfang expressed great interest in this research direction, as both teams share highly aligned research priorities. The discussion was so engaging that the meeting extended 20 minutes beyond schedule, and both sides agreed to further strengthen future collaborations to further develop early diagnosis and innovative treatments for Alzheimer’s disease. The webianr not only deepened Sino-German collaboration but also provided new perspectives on early screening and innovative treatment strategies for Alzheimer’s disease. We look forward to more international exchanges in the future to jointly navigate this global challenge.
